Fractyl Health

A thriving market for initial public offerings is essential for biopharmaceutical industry growth as firms seek to expand drug development programs beyond the scope of what their venture capital backe

Third Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Kyverna Therapeutics Inc. took advantage of the growing excitement for chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of autoimmune diseases by raising $319m in an initial public